APVO Aptevo Therapeutics Inc
Price (delayed)
$0.3183
Market cap
$3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$39.78
Enterprise value
-$42,458
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603,
Highlights
APVO's EPS has surged by 72% year-on-year and by 57% since the previous quarter
The company's debt fell by 13% YoY and by 3.6% QoQ
APVO's net income is down by 43% YoY but it is up by 8% QoQ
Aptevo Therapeutics's equity has shrunk by 73% YoY and by 27% QoQ
The quick ratio has plunged by 51% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of APVO
Market
Valuations
Earnings
Shares outstanding
9.42M
Market cap
$3M
Enterprise value
-$42,458
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$24.95M
EBITDA
-$24.52M
Free cash flow
-$24.3M
Per share
Balance sheet
Liquidity
EPS
-$39.78
Free cash flow per share
-$6.9
Book value per share
$1.09
Revenue per share
$0
TBVPS
$4.24
Total assets
$14.92M
Total liabilities
$10.46M
Debt
$5.03M
Equity
$4.46M
Working capital
$4.16M
Debt to equity
1.13
Current ratio
1.77
Quick ratio
1.49
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-118.1%
Return on equity
-266.1%
Return on invested capital
-389.5%
Return on capital employed
-262.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APVO stock price
How has the Aptevo Therapeutics stock price performed over time
Intraday
-10.31%
1 week
-8.77%
1 month
-23.91%
1 year
-98.2%
YTD
-96%
QTD
4.02%
Financial performance
How have Aptevo Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.95M
Net income
-$24.95M
Gross margin
N/A
Net margin
N/A
APVO's net income is down by 43% YoY but it is up by 8% QoQ
The company's operating income rose by 17% YoY and by 8% QoQ
Growth
What is Aptevo Therapeutics's growth rate over time
Valuation
What is Aptevo Therapeutics stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APVO's EPS has surged by 72% year-on-year and by 57% since the previous quarter
APVO's P/B is 94% below its 5-year quarterly average of 5.0 but 7% above its last 4 quarters average of 0.3
Aptevo Therapeutics's equity has shrunk by 73% YoY and by 27% QoQ
Efficiency
How efficient is Aptevo Therapeutics business performance
The return on equity has dropped by 179% year-on-year and by 21% since the previous quarter
The company's return on invested capital has shrunk by 125% YoY but it rose by 7% QoQ
Aptevo Therapeutics's ROA has plunged by 120% YoY and by 8% from the previous quarter
Dividends
What is APVO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APVO.
Financial health
How did Aptevo Therapeutics financials performed over time
APVO's total assets is 43% higher than its total liabilities
The quick ratio has plunged by 51% YoY and by 9% from the previous quarter
APVO's total assets is down by 48% YoY and by 15% QoQ
The company's debt is 13% higher than its equity
Aptevo Therapeutics's equity has shrunk by 73% YoY and by 27% QoQ
The debt to equity rose by 33% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.